HLB Life Science

067630 · KOSDAQ · South Korea

Public Market Listing

067630KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for HLB Life Science are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
VEGFR2Small molecule
Non-Small Cell Lung CancerHepatocellular Carcinoma
Phase 3
EGFR/HER1, HER2, HER4Small molecule
Non-Small Cell Lung CancerBreast Cancer
HER2-Positive Breast Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
PyrotinibPhase 1/2HER2-expressing Advanced Solid Tumors
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
December 2026 (1)
PyrotinibPhase 1/2Advanced Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
2027 (2)
June 2027 (1)
PyrotinibPhase 3Breast Cancer
Est. primary completion 2027-06 · NCT03980054 · CT.gov ↗
What to watch
July 2027 (1)
ApatinibPhase 2Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026Filing submittedApatinibRivoceranib NDA resubmitted to the FDA after July 2026 CRL
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterApatinibFDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗

Financial reports

No financial reports recorded.